[go: up one dir, main page]

WO2006119779A3 - A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution - Google Patents

A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution Download PDF

Info

Publication number
WO2006119779A3
WO2006119779A3 PCT/DK2006/050019 DK2006050019W WO2006119779A3 WO 2006119779 A3 WO2006119779 A3 WO 2006119779A3 DK 2006050019 W DK2006050019 W DK 2006050019W WO 2006119779 A3 WO2006119779 A3 WO 2006119779A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
solid solution
aldosterone antagonist
active compound
aldosterone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2006/050019
Other languages
French (fr)
Other versions
WO2006119779A2 (en
Inventor
Per Holm
Tomas Norling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Veloxis Pharmaceuticals AS
Original Assignee
Lifecycle Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifecycle Pharma AS filed Critical Lifecycle Pharma AS
Publication of WO2006119779A2 publication Critical patent/WO2006119779A2/en
Publication of WO2006119779A3 publication Critical patent/WO2006119779A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A pharmaceutical composition comprising a therapeutically or prophylactically active compound selected from the group of aldosterone antagonists, wherein the active compound is present as a solid solution.
PCT/DK2006/050019 2005-05-10 2006-05-10 A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution Ceased WO2006119779A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200500678 2005-05-10
DKPA200500678 2005-05-10

Publications (2)

Publication Number Publication Date
WO2006119779A2 WO2006119779A2 (en) 2006-11-16
WO2006119779A3 true WO2006119779A3 (en) 2007-06-14

Family

ID=37396910

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2006/050019 Ceased WO2006119779A2 (en) 2005-05-10 2006-05-10 A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution

Country Status (1)

Country Link
WO (1) WO2006119779A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2908958T3 (en) 2013-02-01 2022-05-04 Grace W R & Co Porous silica gel as a carrier for liquid technologies
KR20220035119A (en) * 2019-06-18 2022-03-21 스트롱브릿지 더블린 리미티드 Dichlorphenamide Compositions and Methods of Use

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769236A (en) * 1982-04-19 1988-09-06 Elan Corporation, Plc Medicaments with a high degree of solubility and method for their production
WO1999026625A1 (en) * 1997-11-21 1999-06-03 Smithkline Beecham Plc Formulations comprising dissolved paroxetine
WO2000071098A1 (en) * 1999-05-24 2000-11-30 Purepac Pharmaceutical Co. A pharmaceutical composition containing an active agent that is maintained in solid amorphous form and method of making the same
WO2003004001A1 (en) * 2001-07-06 2003-01-16 Lifecycle Pharma A/S Controlled agglomeration
US20040077611A1 (en) * 1999-03-05 2004-04-22 G.D. Searle & Co. Triple therapy of angiotensin converting enzyme inhibitor epoxy-steroidal aldosterone antagonist and diuretic or digoxin for treatment of cardiovascular disease
WO2005034908A2 (en) * 2003-10-10 2005-04-21 Lifecycle Pharma A/S A solid dosage form comprising a fibrate and a statin
WO2005053689A2 (en) * 2003-12-01 2005-06-16 Lifecycle Pharma A/S Pharmaceutical compositions comprising lercanidipine

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769236A (en) * 1982-04-19 1988-09-06 Elan Corporation, Plc Medicaments with a high degree of solubility and method for their production
WO1999026625A1 (en) * 1997-11-21 1999-06-03 Smithkline Beecham Plc Formulations comprising dissolved paroxetine
US20040077611A1 (en) * 1999-03-05 2004-04-22 G.D. Searle & Co. Triple therapy of angiotensin converting enzyme inhibitor epoxy-steroidal aldosterone antagonist and diuretic or digoxin for treatment of cardiovascular disease
WO2000071098A1 (en) * 1999-05-24 2000-11-30 Purepac Pharmaceutical Co. A pharmaceutical composition containing an active agent that is maintained in solid amorphous form and method of making the same
WO2003004001A1 (en) * 2001-07-06 2003-01-16 Lifecycle Pharma A/S Controlled agglomeration
WO2005034908A2 (en) * 2003-10-10 2005-04-21 Lifecycle Pharma A/S A solid dosage form comprising a fibrate and a statin
WO2005053689A2 (en) * 2003-12-01 2005-06-16 Lifecycle Pharma A/S Pharmaceutical compositions comprising lercanidipine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HASEGAWA A ET AL: "Physical properties of solid dispersions of poorly water-soluble drugs with enteric coating agents", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 33, no. 8, 1985, pages 3429 - 3435, XP002155096, ISSN: 0009-2363 *
OSAMA ABD ELAZEEM SOLIMAN ET AL: "AMORPHOUS SPIRONOLACTONE-HYDROXYPROPYLATED CYCLODEXTRIN COMPLEXES WITH SUPERIOR DISSOLUTION AND ORAL BIOAVAILABILITY", INTERNATIONAL JOURNAL OF PHARMACEUTICS, AMSTERDAM, NL, vol. 149, no. 1, 1997, pages 73 - 83, XP000990156, ISSN: 0378-5173 *

Also Published As

Publication number Publication date
WO2006119779A2 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
WO2007086001A3 (en) Novel pyridine derivatives
WO2008006528A3 (en) Pharmaceutical compositions comprising levetiracetam
MY154909A (en) Novel thiophene derivatives
TW200700406A (en) Novel thiophene derivatives
WO2008081399A3 (en) 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists
TW200716591A (en) Novel thiophene derivatives
TW200708511A (en) Novel thiophene derivatives
WO2006100635A3 (en) Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
WO2006068826A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
WO2007122581A3 (en) Compositions and kits of phenylephrine
WO2009016560A3 (en) Trans-3-aza-bicyclo[3.1.0]hexane derivatives
WO2008020405A3 (en) Azetidine compounds as orexin receptor antagonists
WO2007028135A3 (en) Imidazopyridine compounds
WO2008064353A3 (en) 7,8-saturated-4,5-epoxy-morphinanium analogs
WO2009057079A3 (en) Novel pyrimidine derivatives
WO2005077932A3 (en) Chemokine receptor antagonists
TW200738670A (en) Novel thiophene derivatives
WO2010056022A3 (en) Melanocortin receptor agonists
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
WO2005067893A3 (en) Pharmaceutical compositions comprising midazolam in a high concentration
WO2007131016A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
WO2007050802A3 (en) Novel opioid antagonists
WO2007014054A3 (en) Benzenesulfonamide inhibitor of ccr2 chemokine receptor
WO2006138735A3 (en) Gel compositions for topical administration
WO2008073863A3 (en) Preparation and utility of substituted allylamines

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06742495

Country of ref document: EP

Kind code of ref document: A2